Enhancing Immunotherapy: New Study Reveals Anti-Inflammatory Strategies for Effective Cancer Treatment
Researchers at the Research Institute of Molecular Pathology in Vienna discovered that combining immunotherapy with anti-inflammatory drugs, like aspirin, can significantly improve cancer treatment in mice. In their study, mice genetically modified to develop human-like tumors lived longer and even achieved complete cures when treated with this combination. Without anti-inflammatories, these mice showed resistance to immunotherapy.
The study identified monocytes, a type of white blood cell, as key players in activating killer T cells, which target cancer. Monocytes can capture cancer cell fragments and present them to T cells, prompting an immune response. However, tumor cells can evade the immune system by increasing production of prostaglandin E2, which inhibits monocyte action, and decreasing interferons, which normally stimulate the immune response.
The researchers suggest that anti-inflammatory drugs could enhance the effectiveness of immunotherapy by blocking prostaglandin E2. They propose various treatment combinations involving immunotherapy, anti-inflammatories, and drugs that boost interferon production. Though this approach has shown success in mouse models of melanoma, pancreatic, lung, and colon cancers, scientists acknowledge that results in humans may vary due to the heterogeneous nature of human tumors.
**What are the potential benefits of combining aspirin with immunotherapy in cancer treatment?**
Interview with Dr. Anna obenauf,Lead Researcher at the Research Institute of Molecular Pathology in Vienna
NewsDirectory3: Thank you for joining us today,Dr. Obenauf.Your recent research on the combination of immunotherapy and anti-inflammatory drugs like aspirin has generated significant interest. Can you summarize the key findings of your study?
Dr. Obenauf: Thank you for having me. Our study revealed that combining immunotherapy with anti-inflammatory drugs significantly improves treatment efficacy in mice with genetically engineered tumors resembling human cancers. We observed that these mice not only lived longer but in certain specific cases, achieved complete cures. Conversely, without anti-inflammatory treatments, the same mice displayed resistance to immunotherapy.
NewsDirectory3: That’s intriguing. Could you explain the underlying mechanisms that make this combination so effective?
Dr. obenauf: Certainly. We found that a type of white blood cell known as monocytes plays a crucial role in activating killer T cells, wich are essential for targeting cancer cells. Monocytes can capture fragments of cancer cells and present them to T cells,thus initiating an immune response. Though,tumors frequently enough escape immune detection by increasing prostaglandin E2,which hampers monocyte function,and by decreasing interferon levels that stimulate immune responses.
Our research suggests that anti-inflammatory drugs can block the action of prostaglandin E2,thereby enhancing the immune response facilitated by monocytes. We are also exploring combinations that include drugs that enhance interferon production alongside immunotherapies.
NewsDirectory3: Your results appear promising across various cancer types. Are you concerned about the potential variability of these results in human patients?
Dr. Obenauf: yes, that is an critically important consideration. While our findings in mouse models of melanoma,pancreatic,lung,and colon cancers are encouraging,human tumors are more heterogeneous. Individual responses to treatment can vary significantly,which is why we are cautious about directly translating these results to clinical settings at this stage.
NewsDirectory3: There have been suggestions about careful drug combinations. Can you elaborate on that?
Dr. Obenauf: Our study suggests that while anti-inflammatories like aspirin can provide short-term benefits in boosting immunotherapy responses, they are unlikely to be a standalone solution due to potential side effects. Therefore, we advocate for carefully designed combinations of therapies to optimize patient outcomes.
NewsDirectory3: What is the current status of clinical trials related to this combination treatment?
Dr. Obenauf: We are actively conducting clinical trials to test various anti-inflammatory drugs beyond aspirin that might be more targeted and effective in enhancing immunotherapy.It’s a vital area of research, and we hope to contribute further insights into optimizing cancer treatments.
NewsDirectory3: Thank you for sharing these insights, Dr.Obenauf. We look forward to following the progress of your research and its implications for cancer treatment.
Dr.Obenauf: Thank you for the prospect to discuss our work. I appreciate your interest and attention to these important developments in cancer research.
Expert biotechnologist Elewaut points out that while these anti-inflammatories can provide short-term benefits, they might not be a sole solution due to potential side effects. Instead, they recommend careful combinations of drugs to optimize outcomes. Head researcher Anna Obenauf mentions that clinical trials are ongoing to explore other more targeted anti-inflammatory drugs besides aspirin.
Marisol Soengas, a cancer research leader, praises the study for its thorough approach. She emphasizes the need for caution and further research before combining anti-inflammatories with standard immunotherapy treatments, such as immune checkpoint inhibitors.